Contact Name:	Miss. Shine deng	Contact Email:	30****0@qq.com
Contact Job Title:	Business Development Manager	Contact Mob:	186***137
Contact Tel:	0731-85525886	Contact Fax:
Address:		Website:

As a leading corporation in the industry of Chinese nano-silver medical anti-infection and traumatic treatment, Anson Biological Technology Co., Ltd., with RMB 174 million of registered fund, has been focusing on the R&D of nano-silver technology for 12 years. The company successively became "CSPGP Council Unit", the first president unit of "Hunan Association for Medical Devices Industry", and was selected "Hunan Giant Enterprises" in 2017, and "Hunan Listed Back-up Enterprise" in 2018, which was specially supported by the Hunan listing-work leading group office. As "Hunan high-tech enterprise", Anson mainly makes technological nano-AG and silver-ion products, and intelligent-interaction traumatic treatment pack products. Medical nano-silver antimicrobial technology is currently one of the best solutions of replacing antibiotic treatment in the field of clinical traumatic anti-infection. Having labored over the medical apparatus for 14 years, the company is familiar with the domestic market, policies and regulations, and access, and has established solid and stable relationship in multiple sectors. It is equipped with rich resources and operating capacity in respect of licenses for registration, production, GMP, access, patents and trademarks and public expense catalog. Currently, the company owns 6 creation patents, 10 practical new-type patents, 2 appearance patents, and more than 20 registered trademarks, and had passed the authentication of medical apparatus 13485 system, ISO9001 quality system and ISO14000 environment quality. It has GMP-standard plan of 30, 000 square meters in the national biological industry base and an over 1600-square-meter management headquarter which is located in Hualing Building, Middle Furong Road, Changsha, both being self-owned. Besides, according to its strategic development planning, a R&D platform has been jointly established by Nanchang University, Central South University and Xiangya Hospital Central South University, which centers the goal of being "expert on traumatic and anti-infection treatment" and works for the R&D of other secondary and third-tier new technological products for traumatic treatment. Exceeding RMB 1 billion of capital market valuation, it has finished the A-round financing and prepared for IPO of China A-stock or Hong Kong Stocks.